Advanced searches left 3/3

Omeprazole - Europe PMC

Summarized by Plex Scholar
Last Updated: 21 June 2022

* If you want to update the article please login/register

Evaluation of gastric pH-dependent drug interaction between famitinib and the commonly used proton pump inhibitor omeprazole in healthy subjects

Aims: : To investigate the potential gastric pH-dependent drug-drug interaction, risk, and tolerability of famitinib co-administered in healthy subjects with omeprazole. On day 10u201314, omeprazole was administered as a single oral 25 mg under a fasting condition, with famitinib on day 15, and on the sequel, seven days later. Following each famitinib dose, blood samples were collected at predetermined time points for both famitinib and its metabolite SHR116637. Results: 0. 989, 0. 956, and 0. 953 respectively. The least-squares geometric mean ratios of C, AUC, and AUC for famitinib were calculated using omeprazole, AUC, and AUC for famitinib alone were 0. 989, 0. 956, and 0. 953, respectively. During the administration phase, 5 patients reported six TEAEs, among which 6 subjects reported 9 TEAEs and 1 subject reported 1 TEAE during famitinib or omeprazole administered alone respectively, while 6 subjects reported 16 treatment emergent adverse events, out of which 6 subjects reported 9 TEAEs and 1 subject reported 1 TEAE during the combined administration phase.

Source link: https://europepmc.org/article/PPR/PPR507955

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions